Federal health officials attacked an Amsterdam-based biotech company seeking approval of a Huntington's disease treatment and accused it of lying

Core Viewpoint - Federal health officials are facing criticism for rejecting rare-disease drugs, specifically targeting an Amsterdam-based biotech company that is seeking approval for a Huntington's disease treatment [1] Group 1 - Federal health officials have been criticized by lawmakers for their recent decisions regarding the approval of drugs for rare diseases [1] - The focus of the criticism is on a biotech company based in Amsterdam that is attempting to gain approval for a treatment aimed at Huntington's disease [1]